Asia-Pacific Liver Disease Treatment Market is expected to
reach USD 2.83 billion by 2021 from USD 1.57 billion in 2016, growing at a CAGR
of 12.51% during the forecast period, 2016-2021.
As the second largest internal organ, liver performs many
complex functions in the body (bile secretion, toxin removal, and fighting
infections, etc.). Malfunctioning of liver can be life-threatening as it can
cause multiple acute and chronic diseases (hepatitis, non-alcoholic fatty liver
disease, liver cancer, liver tumour, and liver cirrhosis, among others). The initial
symptoms of liver damage include nausea, fatigue, diarrhoea, jaundice, swollen
abdomen, and mental disorientation among other. Asia-Pacific is the fastest
growing market for Liver Disease Treatment Drugs. As per recent report, 7% of
population in China are infected by Hepatitis, out of which many are at the
risk of developing chronic liver cancer and cirrhosis. Additionally,
Non-Alcoholic Fatty Liver Disease are now widely prevalent in Asia-Pacific
region.
Browse market data tables and in-depth TOC of the Asia-Pacific
Liver Disease Treatment Market to 2021 @
http://www.marketdataforecast.com/market-reports/asia-pacific-liver-disease-treatment-market-1736/
The growth of Liver Disease Treatment market is majorly
driven by factors such as unorganized lifestyle, rising public awareness,
increasing alcohol consumption, unmet needs for the treatment of liver cancer,
and growing obese and diabetic population.
The key restraints of the market are side-effects of the product
(fatigue, fever, and depression) and competition from alternative medicine
(Herbal, Natural medicine). Herbal medicines have been used for the treatment
of liver for a long time and its use has increasing manifold lately due to
growing domestic manufacturing companies. These products are marketed as safe
with no side-effects, thereby enjoys the trust of the customer. Furthermore,
high cost of the drugs also hinders the growth of Liver Disease Treatment
market.
The Asia-Pacific Liver Disease Treatment Market is segmented
on the basis of Treatment Modality and Disease Type. Based on Treatment
Modality, the market is classified into Antiviral, Vaccines, Chemotherapy,
Immunosuppressive Agents, Corticosteroids, and Others. On the basis of Disease
Type, the market is classified into Hepatitis, Non-Alcoholic Fatty Liver
Disease, Alcohol Induced, Liver Cancer, and Others
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/asia-pacific-liver-disease-treatment-market-1736/request-sample
The Asia-Pacific market is geographically segmented into
China, India, Japan, South Korea and Australia.
The major companies dominating the Asia-Pacific Liver
Disease Treatment Market are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.),
Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland),
Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer
Schering AG (Germany), and AstraZeneca (United Kingdom).
Inquire before buying @ http://www.marketdataforecast.com/market-reports/asia-pacific-liver-disease-treatment-market-1736/inquire
About Us:
Market Data Forecast is a firm working in the area of market
research and business intelligence. With rich experience in research across
various business domains, we cater to the needs of both individual and
corporate clients. Our analyst team comprises expert professionals in market
research, who with their collective knowledge and sksillset dedicatedly serve
clients from various industries and regions.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
